Skip to main content
SpringerLink
Log in

Growth hormone secretion in polytransfused prepubertal patients with homozygous β-thalassemia. Effect of longterm recombinant GH (recGH) therapy

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Growth was monitored in 133 male and 150 female North Sardinian prepubertal patients with homozygous β-thalassemia in order to ascertain the incidence of GH deficiency (GHD) and the effects of long-term recombinant GH (recGH) treatment on growth velocity and bone maturation. A significant reduction in growth velocity and a fall in IGF-I levels was observed in 19 male and 16 female patients (12.3%). Their peak GH responses to GHRH (5.45±0.78 and 4.99±0.86 ng/ml) and clonidine administration (4.21±0.32 and 4.15±0.27 ng/ml in males and females, respectively) were markedly reduced with respect to control subjects (p<0.01). No statistically significant correlation was found between chronological age, number of blood units received, plasma ferritin levels and plasma IGF-I levels as well as with peak GH response to stimulation. Thalassemic patients with GHD had plasma ferritin levels (1382.44±160.34 and 1255.23±139.81 ng/ml in males and females, respectively) significantly lower than those recorded in the other patients (2848.94±283.61 and 3077.82±220.51 ng/ml). Patients with GHD were treated with recGH for an average period of 59 months (range 26–124). Treatment was able to restore growth and to increase significantly plasma IGF-I levels. Growth velocity at the end of the first yr of treatment was 6.78±1.21 and 6.11±0.85 cm/yr in males and females, respectively. Growth velocity values and plasma IGF-I levels remained significantly higher than basal values throughout the period of treatment. However, treatment was unable to normalize bone maturation since bone age values were always reduced with respect to chronological age. No incidence of side effects was observed. These data indicate that GHD, when present, is one but not the sole cause of delayed bone maturation and height deficiency in thalassemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Danesi L, Scacchi M, De Martin M, et al. Evaluation of hypothalamic- pituitary function in patients with thalassemia major. J Endocrinol Invest 1992, 15: 177–84.

    Article  PubMed  CAS  Google Scholar 

  2. Masala A, Meloni T, Gallisai D, Alagna S, Rovasio PP, Rassu S. Endocrine functioning in multitransfused prepubertal patients with homozygous β-thalassemia. J Clin Endocrinol Metab 1984, 58: 667–70.

    Article  PubMed  CAS  Google Scholar 

  3. McIntosh N. Endocrinopathy in thalassemia major. Arch Dis Child 1976, 51: 195.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Italian Working Group on Endocrine Complications in Non-Endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol (Oxf) 1995, 42: 581–6.

    Article  Google Scholar 

  5. Tiosano D, Hochberg Z. Endocrine complications of thalassemia. J Endocrinol Invest 2001, 24: 716–23.

    Article  PubMed  CAS  Google Scholar 

  6. Low LCK, Kwan EYW, Lim YJ, Lee ACW, Tam CF, Lam KSL. Growth hormone treatment of short chinese children with β-thalassemia major without GH deficiency. Clin Endocrinol (Oxf) 1995, 42: 359–63.

    Article  CAS  Google Scholar 

  7. Pintor C, Cella SG, Manso P, et al. Impaired growth hormone (GH) response to GH releasing hormone in thalassemia major. J Clin Endocrinol Metab 1986, 62: 263–7.

    Article  PubMed  CAS  Google Scholar 

  8. Katzos G, Harsoulis F, Papadopoulou M, Athanasiou M, Sava K. Circadian growth hormone secretion in short multitransfused prepubertal children with thalassemia major. Eur J Ped 1995, 154: 445–9.

    Article  CAS  Google Scholar 

  9. Scacchi M, Danesi L, De Martin M, et al. Treatment with biosynthetic growth hormone of short thalassemic patients with impaired growth hormone secretion. Clin Endocrinol (Oxf) 1991, 35: 335–9.

    Article  CAS  Google Scholar 

  10. Low LCK, Postel-Vinay MC, Kwan EYV, Cheung PT. Serum growth hormone (GH) binding protein, IGF-I and IGFBP-3 in patients with β-thalassemia major and the effect of GH treatment. Clin Endocrinol (Oxf) 1998, 48: 641–6.

    Article  CAS  Google Scholar 

  11. Theodoridis C, Ladis V, Papatheodorou A, et al. Growth and management of short stature in thalassemia major. Pediatr Endocrinol Metab 1998, 11: 835–44.

    Google Scholar 

  12. Katzsos G, Papakostantinou-Athanasiadou E, Athanasiou-Metaxa M, Harsoulis F. Growth hormone treatment in short children with beta-thalassemia major. J Pediatr Endocrinol Metab 2000, 131: 163–70.

    Google Scholar 

  13. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976, 51: 170–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  14. Vannasaeng S, Fucharoen S, Poutrakul P, Ploybutr S, Yansukon P. Pituitary function in thalassemic patients and the effect of chelation therapy. Acta Endocrinol (Copenh) 1991, 124: 23–30.

    CAS  Google Scholar 

  15. Vassillopoulou-Sellin R, Ojedeji CO, Foster PL, Thompson MM, Saman NA. Hemoglobin as a direct inhibitor of cartilage growth in vitro. Horm Metab Res 1989, 21: 11–4.

    Article  Google Scholar 

  16. De Virgilis S, Congia M, Frau F, et al. Desferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988, 113: 661–9.

    Article  Google Scholar 

  17. Cavallo L, Gurrado R, Gallo F, Zecchino C, De Mattia D, Tatò L. Growth deficiency in polytransfused ?-thalassemia patients is not growth hormone dependent. Clin Endocrinol (Oxf) 1997, 46: 701–6.

    Article  CAS  Google Scholar 

  18. Garcia-Mayor RV, Andrade Olivie A, Fernandez Catalina P, Castro M, Rego Iraeta A, Reparaz A. Linear growth in thalassemic children treated with intensive chelation therapy. A longitudinal study. Horm Res 1993, 40: 189–93.

    Article  PubMed  CAS  Google Scholar 

  19. Brill PV, Winchester P, Giardina PI, Cunningham-Rundles S. Desferrioxamine induced bone dysplasia in patients with thalassemia major. Am J Roentgenol 1991, 156: 561–5.

    Article  CAS  Google Scholar 

  20. Naselli A, Vignolo M, Di Battista E, et al. Long-term follow- up of skeletal dysplasia in thalassemia major. J Pediatr Endocrinol Metab 1998, 11 (Suppl 3): 817–25.

    PubMed  Google Scholar 

  21. Olivieri NF, Koren G, Harris J, et al. Growth failure and body changes induced by desferrioxamine. Am J Pediatr Hematol Oncol 1992, 14: 48–56.

    Article  PubMed  CAS  Google Scholar 

  22. De Sanctis V, Pinamonti A, Di Palma A., et al. Growth and development in thalassemia major patients with severe bone lesions due to desferroxamine. Eur J Pediatr 1996, 155: 368–72.

    Article  PubMed  Google Scholar 

  23. Cavallo L, Licci D, Acquafredda A, et al. Endocrine involvment in children with β-thalassemia major. Transversal and longitudinal studies. I. Pituitary-thyroidal axis function and is correlation with serum ferritin levels. Acta Endocrinol (Copenh) 1984, 107: 49–53.

    CAS  Google Scholar 

  24. Frasier SD. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr Rev 1983, 4: 155–70.

    Article  PubMed  CAS  Google Scholar 

  25. Chrysis DC, Alexandrides TK, Koromantzou E, et al Novel application of IGF-I and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with β-thalassemia. Clin Endocrinol (Oxf) 2001, 54: 253–9.

    Article  CAS  Google Scholar 

  26. Masala A, Meloni T, Alagna S, et al. Plasma growth hormone (GH) and somatomedin-C (SM-C) levels in patients with homozygous β-thalassemia. Exp Clin Endocrinol 1988, 7: 161–3

    Google Scholar 

  27. Masala A, Meloni T, Gallisai D, et al. The effects of thyrotropin releasing hormone and luteinizing hormone releasing hormone on growth hormone release in patients with homozygous β-thalassemia. J Clin Endocrinol Metab 1982, 54: 1271–74.

    Article  PubMed  CAS  Google Scholar 

  28. Masala A, Alagna S, Faedda R, et al. Paradoxical growth hormone (GH) release in response to thyrotropin releasing hormone (TRH) in patients with Wilson’s disease. J Nucl Med All Sci 1987, 31: 104–5.

    Google Scholar 

  29. Berkovitch M, Bistritzer T, Milone SD, Perlman K, Kucharczyk W, Olivieri NF. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J Pediatr Endocrinol Metab 2000, 13: 179–84.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Struttura Clinica Medica-Patologia Medica, Istituto di Patologia Medica, Viale S. Pietro 8, 07100, Sassari, Italy

    Antonio Masala, M. M. Atzeni, S. Alagna, P. P. Rovasio & P. Gallo

  2. Clinica Pediatrica, University of Sassari, Sassari, Italy

    D. Gallisai, C. Burrai & M. G. Mela

Authors
  1. Antonio Masala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. M. Atzeni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Alagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Gallisai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Burrai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. G. Mela
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. P. Rovasio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Gallo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Masala.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masala, A., Atzeni, M.M., Alagna, S. et al. Growth hormone secretion in polytransfused prepubertal patients with homozygous β-thalassemia. Effect of longterm recombinant GH (recGH) therapy. J Endocrinol Invest 26, 623–628 (2003). https://doi.org/10.1007/BF03347019

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347019

Keywords

Search

Navigation